New combination treatment could benefit T-ALL patients who do not respond to chemotherapy

T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this.